Engineered nanoparticulate drug delivery systems: the next frontier for oral administration

AAPS Journal

Volumn 14, Issue 4, 2012, Pages 688-702

  Diab, Roudayna ^a   Jaafar Maalej, Chiraz ^b   Fessi, Hatem ^b   Maincent, Philippe ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Biodegradable; Nanoparticles; Natural; Oral; Polymer

Indexed keywords

ALBUMIN; ALGINIC ACID; AMIKACIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CARBAZOLE DERIVATIVE; CHITOSAN; CHITOSAN DERIVATIVE; COPOLYMER; DNA VACCINE; ETHAMBUTOL; EUDRAGIT; GELATIN; GLIADIN; GLICLAZIDE; HEPATITIS B ANTIGEN; INSULIN; ISONIAZID; LAMIVUDINE; LIPOSOME; NANOPARTICLE; PLASMID DNA; POLYCAPROLACTONE; POLYESTER; POLYMETHACRYLIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; SOLID LIPID NANOPARTICLE; STREPTOMYCIN; UNINDEXED DRUG;

DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; ENCAPSULATION; ENGINEERED NANOPARTICULATE DRUG DELIVERY SYSTEM; GASTROINTESTINAL SECRETION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; SUSTAINED DRUG RELEASE; SWINE INFLUENZA; TUBERCULOSIS;

ADMINISTRATION, ORAL; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; INTESTINAL ABSORPTION; LIPIDS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYMERS; SOLUBILITY;

EID: 84869107207     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9377-y     Document Type: Review

References (110)

1. Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos. 2003;31:1507-19.
2. Panchagnula R, Thomas NS. Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm. 2000;201:131-50.
3. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 1996;56:1296-302.
4. Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci. 2008;97:1109-34.
5. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22-33.
6. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine. 2006;1:117-28.
7. Sosnik A, Carcaboso A, Chiappetta D. Polymeric nanocarriers: new endeavors for the optimization of the technological aspects of drugs. Recent Patents Biomed Eng. 2008;1:43-59.
8. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target. 2004;12:65-70.
9. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172:1487-90.
10. Brayden DJ, Baird AW. Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery. Adv Drug Deliv Rev. 2004;56:721-6.
11. des Rieux A, Fievez V, Garinot M, Schneider Y, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116: 1-27.
12. Lamprecht A. IBD: selective nanoparticle adhesion can enhance colitis therapy. Nat Rev Gastroenterol Hepatol. 2010;7:311-2.
13. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev. 2010;62:28-41.
14. Löbenberg R, Araujo I, Kreuter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur J Pharm Biopharm. 1997;44:127-32.
15. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 2004;54:761-6.
16. Pandey R, Khuller GK. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother. 2006;57:1146-52.
17. Plapied L, Vandermeulen G, Vroman B, Préat V, des Rieux A. Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery. Int J Pharm. 2010;398:210-8.
18. Laurienzo P. Marine polysaccharides in pharmaceutical applications: an overview. Mar Drugs. 2010;8:2435-65.
19. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res. 1994;11:1186-9.
20. Schipper NG, Vârum KM, Stenberg P, Ocklind G, Lennernäs H, Artursson P. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. Eur J Pharm Sci. 1999;8:335-43.
21. Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Vårum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res. 1997;14:923-9.
22. Schipper NG, Vårum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res. 1996;13:1686-92.
23. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res. 2007;24:2198-206.
24. Lu E, Franzblau S, Onyuksel H, Popescu C. Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul. 2009;26:346-54.
25. Chew JL, Wolfowicz CB, Mao H, Leong KW, Chua KY. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine. 2003;21:2720-9.
26. Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci. 2007;32:278-90.
27. Zhao K, Shi X, Zhao Y, Wei H, Sun Q, Huang T, et al. Preparation and immunological effectiveness of a swine influenza DNAvaccine encapsulated in chitosan nanoparticles. Vaccine. 2011;29:8549-56.
28. Mao S, SunW,Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62:12-27.
29. Ohya Y, Shiratania M, Kobayashia H, Ouchia T. Release behavior of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity. J Macromolecular Sci Pure Appl Chem. 1994; doi: 10.1080/10601329409349743
30. Zhang S, Kawakami K. One-step preparation of chitosan solid nanoparticles by electrospray deposition. Int J Pharm. 2010;397:211-7.
31. Jain A, Jain SK. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci. 2008;35:404-16.
32. Bayat A, Dorkoosh FA, Dehpour AR, Moezi L, Larijani B, Junginger HE, et al. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm. 2008;356:259-66.
33. Zhang H, Neau SH. In vitro degradation of chitosan by bacterial enzymes from rat cecal and colonic contents. Biomaterials. 2002;23:2761-6.
34. Jain A, Jain SK, Ganesh N, Barve J, Beg AM. Design and development of ligand-Appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine. 2010;6:179-90.
35. Atyabi F, Talaie F, Dinarvand R. Thiolated chitosan nanoparticles as an oral delivery system for amikacin: in vitro and ex vivo evaluations. J Nanosci Nanotechnol. 2009;9:4593-603.
36. Malhotra M, Lane C, Tomaro-Duchesneau C, Saha S, Prakash S. Anovel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. Int J Nanomedicine. 2011;6:485-94.
37. Wang Q, Jamal S, Detamore MS, Berkland C. PLGA-chitosan/PLGA-Alginate nanoparticle blends as biodegradable colloidal gels for seeding human umbilical cord mesenchymal stem cells. J Biomed Mater Res A. 2011;96:520-7.
38. Smidsrød O, Skjåk-Braek G. Alginate as immobilization matrix for cells. Trends Biotechnol. 1990;8:71-8.
39. Sonavane GS, Devarajan PV. Preparation of alginate nanoparticles using Eudragit E100 as a new complexing agent: development, in-vitro, and in-vivo evaluation. J Biomed Nanotech. 2007;3:160-9.
40. Rajaonarivony M, Vauthier C, Couarraze G, Puisieux F, Couvreur P. Development of a new drug carrier made from alginate. J Pharm Sci. 1993;82:912-7.
41. Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 2006;48:171-6.
42. Arangoa MA, Campanero MA, Renedo MJ, Ponchel G, Irache JM. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res. 2001;18:1521-7.
43. Patil GV. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev Res. 2003;58:219-47.
44. Toshio Y, Mitsuru H, Shozo M, Hitoshi S. Specific delivery of mitomycin C to the liver, spleen, and lung: nano-And microspherical carriers of gelatin. Int J Pharm. 1981;8:131-41.
45. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003;257:169-80.
46. LinW,CoombesAG,DaviesMC, Davis SS, IllumL. Preparation of sub-100 nm human serum albumin nanospheres using a pHcoacervation method. J Drug Target. 1993;1:237-43.
47. Kumar PV, JainNK. Suppression of agglomeration of ciprofloxacinloaded human serum albumin nanoparticles. AAPS Pharm Sci Technol. 2007;8:17.
48. Umamaheshwari RB, Jain NK. Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Target. 2003;11:415-24.
49. Bhavsar MD, Amiji MM. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release. 2007;119:339-48.
50. Roy S, Pal K, Anis A, Pramanik K, Prabhakar B. Polymers in mucoadhesive drug delivery system: a brief note. Des Monomers Polym. 2009;12:483-95.
51. Wang W, Chen H, Liang W. Study on polymethacrylate nanoparticles as delivery system of antisense oligodeoxynucleotides. Yao Xue Xue Bao. 2003;38:298-301.
52. Gargouri M, Sapin A, Bouli S, Becuwe P, Merlin JL, Maincent P. Optimization of a new non-viral vector for transfection: Eudragit nanoparticles for the delivery of a DNA plasmid. Technol Cancer Res Treat. 2009;8:433-44.
53. Jiao YY, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Maincent P. Preparation and in vitro evaluation of heparinloaded polymeric nanoparticles. Drug Deliv. 2001;8:135-41.
54. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation. 2002;105:230-5.
55. Attivi D, Wehrle P, Ubrich N, Damge C, Hoffman M, Maincent P. Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug Dev Ind Pharm. 2005;31:179-89.
56. Tamizhrasi S, Shukla A, Shivkumar T, Rathi V, Rathi JC. Formulation and evaluation of lamivudine loaded polymethacrylic acid nanoparticles. Int J Pharm Technol Res. 2009;1:411-5.
57. Leroux JC, Cozens R, Roesel JL, Galli B, Kubel F, Doelker E, et al. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J Pharm Sci. 1995;84:1387-91.
58. Jelvehgari M, Zakeri-Milani P, Siahi-Shadbad MR, Loveymi BD, Nokhodchi A, Azari Z, et al. Development of pH-sensitive insulin nanoparticles using Eudragit L100-55 and chitosan with different molecular weights. AAPS Pharm Sci Technol. 2010;11:1237-42.
59. Gupta MK, Mishra B, Prakash D, Rai SK. Nanoparticulate drug delivery system of cyclosporine. Int J Pharm Pharm Sci. 2009;1:81-92.
60. Eerikäinen H, Kauppinen EI. Preparation of polymeric nanoparticles containing corticosteroid by a novel aerosol flow reactor method. Int J Pharm. 2003;263:69-83.
61. Xiong X, Tam K. Hydrolytic degradation of pluronic F127/poly (lactic acid) block copolymer nanoparticles. Macromolecules. 2004;37:3425-30.
62. Dash TK, Konkimalla VB. Poly-?-caprolactone based formulations for drug delivery and tissue engineering: a review. J Control Release. 2011. doi:10.1016/j.jconrel.2011.09.064.
63. Chawla JS, Amiji MM. Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-Targeted delivery of tamoxifen. Int J Pharm. 2002;249:127-38.
64. Varela MC, Guzmán M, Molpeceres J, del Rosario Aberturas M, Rodríguez-Puyol D, Rodríguez-Puyol M. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur J Pharm Sci. 2001;12:471-8.
65. Xiong XY, Li YP, Li ZL, Zhou CL, Tam KC, Liu ZY, et al. Vesicles from pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Control Release. 2007;120:11-7.
66. Cegnar M, Kos J, Kristl J. Cystatin incorporated in poly(lactideco- glycolide) nanoparticles: development and fundamental studies on preservation of its activity. Eur J Pharm Sci. 2004;22:357-64.
67. Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release. 2002;78:15-24.
68. Garinot M, Fiévez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release. 2007;120:195-204.
69. Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Annu Rev Anal Chem (Palo Alto Calif). 2008;1:801-32.
70. Villasmil-Sánchez S, Drhimeur W, Ospino SCS, Rabasco Alvarez AM, González-Rodríguez ML. Positively and negatively charged liposomes as carriers for transdermal delivery of sumatriptan: in vitro characterization. Drug Dev Ind Pharm. 2010;36:666-75.
71. Dial EJ, Rooijakkers SHM, Darling RL, Romero JJ, Lichtenberger LM. Role of phosphatidylcholine saturation in preventing bile salt toxicity to gastrointestinal epithelia and membranes. J Gastroenterol Hepatol. 2008;23:430-6.
72. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231-48.
73. Sun J, Deng Y, Wang S, Cao J, Gao X, Dong X. Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation. Drug Deliv. 2010;17:164-70.
74. Ling SSN, Yuen KH, Magosso E, Barker SA. Oral bioavailability enhancement of a hydrophilic drug delivered via folic acidcoupled liposomes in rats. J Pharm Pharmacol. 2009;61:445-9.
75. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-77.
76. Souto E, Müller R. Lipid nanoparticles (SLN and NLC) for drug delivery. In: Domb AJ, Tabata Y, Kumar MNVR, Farber S, editors. Nanoparticles for pharmaceutical applications. California: American Scientific Publishers; 2007. p. 103-22.
77. Tomoyasu Y, Yasuda T, et al. Liposome-encapsulated midazolam for oral administration. J Liposome Res. 2011;21:166-72.
78. Cao J, Sun J, et al. N-Trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev Ind Pharm. 2009;35:1339-47.
79. Sun W, Zhang N, et al. Preparation and evaluation of N(3)-Otoluyl- fluorouracil-loaded liposomes. Int J Pharm. 2008;353:243-50.
80. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2:289-300.
81. Garcia-Fuentes M, Torres D, Alonso M. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloid Surf B. 2003;27:159-68.
82. Olbrich C, Müller RH. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm. 1999;180:31-9.
83. Barauskas J, Johnsson M, Tiberg F. Self-Assembled lipid superstructures: beyond vesicles and liposomes. Nano Lett. 2005;5:1615-9.
84. Lai J, Chen J, Lu Y, Sun J, Hu F, Yin Z, et al. Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS Pharm Sci Technol. 2009;10:960-6.
85. Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporineAencapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine. 2010;5:13-23.
86. Parhi P, Mohanty C, Sahoo SK. Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy. Acta Biomater. 2011;7:3656-69.
87. Luo Y, Chen D, et al. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114:53-9.
88. Hu L, Tang X, et al. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004;56:1527-35.
89. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95:627-38.
90. Suresh G, Manjunath K, et al. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech. 2007;8:24.
91. Pandey R, Sharma S, et al. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb). 2005;85:415-20.
92. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49:N309-15.
93. Joshi HM, Bhumkar DR, Joshi K, Pokharkar V, Sastry M. Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir. 2006;22:300-5.
94. Hillyer JF, Albrecht RM. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci. 2001;90:1927-36.
95. Stern A, Rotem D, Popov I, Porath D. Quasi 3D imaging of DNA-gold nanoparticle tetrahedral structures. J Phys Condens Matter. 2012;24:164203.
96. You C, Agasti S, Park M, Rotello V. Chemical and biological sensing based on gold nanoparticles. In: Mattoussi H, Cheon J, editors. Inorganic nanoprobes for biological sensing and imaging. Norwood: Artech House Inc.; 2009. p. 161-95.
97. Jana N, Gearheart L, Murphy C. Seed-mediated growth approach for shape-controlled synthesis of spheroidal and rod-like gold nanoparticles using a surfactant template. Adv Mater. 2001;13:1389-93.
98. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir. 2005;21:10644-54.
99. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1:325-7.
100. Dhar S, Reddy EM, Prabhune A, Pokharkar V, Shiras A, Prasad BLV. Cytotoxicity of sophorolipid-gellan gum-gold nanoparticle conjugates and their doxorubicin loaded derivatives towards human glioma and human glioma stem cell lines. Nanoscale. 2011;3:575-80.
101. Zhang X, Wu H, Wu D, Wang Y, Chang J, Zhai Z, et al. Toxicologic effects of gold nanoparticles in vivo by different administration routes. Int J Nanomedicine. 2010;5:771-81.
102. Liu Y, Miyoshi H, Nakamura M. Novel drug delivery system of hollow mesoporous silica nanocapsules with thin shells: preparation and fluorescein isothiocyanate (FITC) release kinetics. Colloids Surf B Biointerfaces. 2007;58:180-7.
103. Moulari B, Pertuit D, Pellequer Y, Lamprecht A. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials. 2008;29:4554-60.
104. Chang J, Chang KLB, Hwang D, Kong Z. In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. Environ Sci Technol. 2007;41:2064-8.
105. Beck J, Vartuli J, Roth W, Leonowicz M, Kresge C, Schmitt K, et al. A new family of mesoporous molecular sieves prepared with liquid crystal templates. J Am Chem Soc. 1992;114:10834-43.
106. Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed Engl. 2007;46:7548-58.
107. Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur J Pharm Biopharm. 2004;57:533-40.
108. Zhang Y, Zhi Z, Jiang T, Zhang J, Wang Z, Wang S. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release. 2010;145:257-63.
109. Li Z, Zhu S, Gan K, Zhang Q, Zeng Z, Zhou Y, et al. Poly-Llysine-modified silica nanoparticles: a potential oral gene delivery system. J Nanosci Nanotechnol. 2005;5:1199-203.
110. Balas F, Manzano M, Horcajada P, Vallet-Regí M. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc. 2006;128:8116-7.